Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro with Lispro in a Basal-Bolus Regimen in Patients with Type 2 Diabetes: PRONTO-T2D
Figures are generally photos, graphs and static images that would be represented in traditional pdf publications.
To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in patients with type 2 diabetes on a basal-bolus insulin regimen.
RESEARCH DESIGN AND METHODS
This was a Phase 3, treat-to-target, double-blind 26-week study. After an 8-week lead-in to optimize basal insulin glargine or degludec in combination with prandial lispro treatment, patients were randomized to blinded URLi (n=336) or lispro (n=337) injected 0 to 2 minutes prior to meals. Patients could continue metformin and/or sodium glucose co-transporter-2 inhibitor. The primary end point was change from baseline HbA1c to 26 weeks (noninferiority margin 0.4%), with multiplicity adjusted objectives for postprandial glucose (PPG) excursions during a standardized meal test.
HbA1c improved for both URLi and lispro and noninferiority was confirmed: estimated treatment difference (ETD) +0.06% (95% CI -0.05; 0.16). Mean change in HbA1C was -0.38% for URLi and -0.43% for lispro, with an end of treatment HbA1c of 6.92% and 6.86% respectively. URLi was superior to lispro in controlling 1- and 2-h PPG excursions: 1-hour ETD, -0.66 mmol/L (95% CI -1.01, -0.30); 2-hour ETD, -0.96 mmol/L (-1.41, -0.52). Significantly lower PPG excursions were evident from 0.5 to 4 hours postmeal with URLi treatment. There were no significant treatment differences in rates of severe or documented hypoglycemia (<3 mmol/L). Incidence of overall treatment-emergent adverse events was similar between treatments.
URLi compared with lispro in a basal-bolus regimen was confirmed to be noninferior for HbA1c and superior to lispro for PPG control in patients with type 2 diabetes.